Aptiom FDA Approval History
FDA Approved: Yes (First approved November 8, 2013)
Brand name: Aptiom
Generic name: eslicarbazepine acetate
Dosage form: Tablets
Previous Name: Stedesa
Company: Sunovion Pharmaceuticals Inc.
Treatment for: Epilepsy, Seizures
Aptiom (eslicarbazepine acetate) is a voltage-gated sodium channel blocker for the treatment of partial-onset seizures in patients with epilepsy.
Development timeline for Aptiom
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.